City of Hope Selects TrialMaster to support clinical trials
OmniComm Systems, Inc. to deploy
a Technology Transfer of the TrialMaster® electronic data
capture (EDC) solution for clinical data collection
FT. LAUDERDALE, FL – July 11, 2007 – /MarketWire/ -
OmniComm Systems, Inc. (OTC Bulletin Board: OMCM), one of the
fastest growing companies in the Electronic Data Capture (EDC)
marketplace, today announced that City of Hope has selected
OmniComm’s EDC solution, TrialMaster and has entered into
negotiations on the contract to support its clinical trials,
including Principal Investigator initiated and federally funded
trials. City of Hope also plans to utilize the OmniComm solution to
provide EDC capabilities for the California Cancer Consortium which
is comprised of City of Hope, UC Davis Cancer Center, University of
Southern California/Norris Comprehensive Cancer Center, University
of Pittsburgh Cancer Institute and affiliated sites. OmniComm
also announced that it will work with City of Hope to establish an
annual Users Group meeting to be held at the City of Hope campus in
Duarte, California.
“OmniComm is truly honored to be chosen as the first line EDC
solution by City of Hope,” said Cornelis F. Wit, CEO of
OmniComm. “Our consulting services team looks forward to
delivering superior support and training services to City of Hope
as they transition to bring TrialMaster in-house.”
“Our extensive experience in conducting oncology trials has
uniquely positioned us to be able to provide the solutions and
support that are specific to the operational environment of the
cancer centers,” said Stephen Johnson, Sr. VP of Business
Development at OmniComm. “We are looking forward to working
in tandem with City of Hope to develop a library of National Cancer
Institute (NCI)-elated reusable electronic case report forms
(eCRFs) and to developing product enhancements that will support
the full technology transfer of TrialMaster to City of
Hope.”
At any given time, City of Hope conducts more than 300 clinical
trials encompassing prevention, screening, treatment, symptom
management and quality of life.
Joyce Niland, Ph.D., the Edward and Estelle Alexander Chair in
Information Sciences and Associate Director for Information
Sciences at City of Hope Cancer Center, states, “As an
NCI-designated Comprehensive Cancer Center, with a long history of
leading edge research and biomedical informatics development,
adopting the OmniComm product has great potential to further
enhance City of Hope’s clinical trials enterprise. We are
excited to work with OmniComm to integrate emerging national and
international standards into this product, such as the CDISC
Protocol Representation, the BRIDG information model, and the NCI
caBIG modules. We look forward to hosting an interactive and
productive OmniComm User Group on our campus over the coming
years."
About OmniComm
OmniComm Systems, Inc. (www.OmniComm.com) provides
customer-driven Internet solutions to pharmaceutical,
biotechnology, research and medical device organizations that
conduct life changing clinical trial research. OmniComm’s
growing base of satisfied customers is a direct result of the
company’s commitment to deliver products and services that
ensure ease of use, faster study build, ease of integration and
better performance. OmniComm’s client intuitive pricing model
allows companies that range from small to mid-size to large scale
institutions to safely and efficiently capitalize on their clinical
research investments.
OmniComm ranked in the top 150 as one of the fastest revenue growth
technology companies in North America during the last 5 years. In a
market overview titled “The Promise of Next-Gen eClinical
Trial Software” by Forrester Research, OmniComm was given the
highest rating among its competitors for industry middleware.
OmniComm Systems Inc. has corporate headquarters in Ft. Lauderdale,
Florida with offices in Bonn, Germany, California, Maryland, New
York, North Carolina and Texas.
Safe Harbor Disclaimer
Statements about OmniComm’s future expectations, including
without limitation, future revenues and earnings, plans and
objectives for the future operations, future agreements, future
economic performance, operations and all other statements in this
press release other than historical facts are "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934, and as
that term is defined in the Private Securities Litigation Reform
Act of 1995. OmniComm intends that such forward-looking statements
be subject to the Safe Harbors created thereby. Since these
statements involve risks and uncertainties, including but not
limited to economic competitive, governmental, contractual and
technological factors affecting OmniComm’s operations,
markets and profitability, actual results could differ materially
and adversely from the expected results.
CONTACT:
Lizanne Kelley
OmniComm Systems, Inc.
954-473-1254 Extension 283
lkelley@omnicomm.com
Posted: July 2007
